Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial

A targeted drug offers new treatment options for patients with specific fibroblast growth factor mutations.

What the study was

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.